FFPE tissue sections were stained with the Dako PD-L1 22C3 pharmDx kit (Agilent Technologies, Santa Clara, CA, USA). In previous studies, PD-L1 immunohistochemistry (IHC) was scored by either combined positive score (CPS) or tumor proportion score (TPS), since there is no recommended PD-L1 evaluation criteria for ICI treatment in NEN heretofore [36 (link),37 (link),38 (link)]. CPS represents the percentage of the number of PD-L1 positive cells, including tumor cells, lymphocytes, and macrophages, to the total number of viable tumor cells, whereas TPS only notes the proportion of PD-L1 positive tumor cells [14 (link)]. In this study, two board-certificated pathologists (S.C. and S.K.) independently interpreted the PD-L1 22C3 IHC slides and then made a consensus CPS.
Free full text: Click here